ReportWire

Tag: Genetics

  • Ground-breaking new method for multi-cancer early detection

    Ground-breaking new method for multi-cancer early detection

    [ad_1]

    Newswise — When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for. An international study led by researchers from Chalmers University of Technology, Sweden, shows that a new, previously untested method can easily find multiple types of newly formed cancers at the same time – including cancer types that are difficult to detect with comparable methods.

    Cancer is one of the deadliest diseases in the world and is more difficult to cure when detected at a late stage.

    Finding effective methods for early detection of several types of cancer at the same time, so-called Multi-Cancer Early Detection (MCED), is an emerging research area. Today’s established screening tests are cancer type-specific, which means that patients need to be tested for each cancer type separately. Emerging MCED tests under development are usually based on genetics, for example measuring DNA fragments from tumours circulating in the blood. But DNA-based methods can only detect some types of cancer and have limited ability to find tumours at the earliest stage, so called stage I.

    New method based on human metabolism
    Now, in an international collaboration, researchers from Chalmers have developed a new method for multi-cancer early detection that is instead based on human metabolism. The results, which have been published in the scientific journal PNAS, uncover new opportunities for cheaper and more effective cancer screening. In a study totalling 1 260 participants, the researchers first discovered that the new method could detect all 14 cancer types that were tested. Next, they showed that twice as many stage I cancers in asymptomatic healthy people can be detected with the new method compared to the emerging DNA-based MCED tests.

    “This is a previously unexplored method, and thanks to the fact that we have been able to test it in a large population, we can show that it is effective in finding more stage I cancers and more cancer types. The method makes it possible to find cancer types that are not screened for today and cannot be found with DNA-based MCED tests, such as brain tumours and kidney cancer,” says Francesco Gatto, who is a visiting researcher at the Department of Biology and Biological Engineering at Chalmers and one of the study’s authors.

    Cheaper and more practical tests
    The method is based on a discovery by Dr. Francesco Gatto and Prof. Jens Nielsen at Chalmers almost ten years ago: that so-called glycosaminoglycans – a type of sugar that is an important part of our metabolism – are excellent biomarkers to detect cancer noninvasively. The researchers developed a machine learning method in which algorithms are used to find cancer-indicating changes in the glycosaminoglycans. The method uses comparatively small volumes of blood or urine, which makes them more practical and cheaper to use.

    “The fact that the method is comparatively simple means that the cost will be significantly low, ultimately enabling more people to have access to and take the test,” says Francesco Gatto.

    Important step towards effective multi-cancer tests
    In the next step, the researchers hope to be able to conduct a study with even more participants to further develop and confirm the method’s potential for screening use.

    “This is a ground-breaking study that gives us hope that one day society will be able to create screening programmes that can detect all cancer types early,” says Francesco Gatto.

    “To be able to find more cancer cases early, we know that new tools are needed. These results are very promising because of the demonstrated higher sensitivity across more types of cancer at stage I, using a cost-efficient and accessible technology,” says Dr. Eric Jonasch, MD, Professor at The University of Texas MD Anderson Cancer Center and co-author of the study.

    The article “Non-invasive multi-cancer early detection using glycosaminoglycans” has been published in the scientific journal Proceedings of the National Academy of Sciences (PNAS).

    • The study has been led by researchers from Chalmers in collaboration with over 30 partners at 10 different universities and research institutes in Sweden and internationally. These are:  Lund University, Sweden, Uppsala University, Sweden, Sahlgrenska Academy at University of Gothenburg, Sweden, Karolinska Institute, Sweden, Vancouver Prostate Centre, Canada, University of British Columbia, Canada, Università Vita-Salute San Raffaele, Italy, University of Modena and Reggio Emilia, Italy, University of Texas MD Anderson Cancer Center, USA, and University of Copenhagen, Denmark.
    • The method has already taken the step into society through the start-up company Elypta, which is one of Chalmers Ventures’ portfolio companies. Elypta is based on the research presented in the scientific study and focus on developing and commercialising MCED tests as well as a test for recurrent kidney cancer. In addition, Elypta has developed the measurement methods used to support the study analysis.

    More about the research
    The study shows that a method based on analysing changes in glycosaminoglycans – a type of sugar that is an important part of our metabolism – can be used to detect several different cancer types at an early stage from the same blood and urine sample, even cancer types that are difficult to detect with other methods.  The researchers chose to test 14 different cancer types, representing the majority of newly diagnosed cancers, and all 14 types could be detected with the new method. 1 260 people participated in the study, both healthy and previously diagnosed with cancer.  With this new method of multi-cancer early detection (MCED), twice as many cases of cancer at its earliest stage (stage I) in otherwise asymptomatic healthy people could be detected compared to other DNA-based MCED tests under development.

    [ad_2]

    Chalmers University of Technology

    Source link

  • More flexible than previously thought: Worms give us new insights into the evolution and diversification of TGF-β signaling pathways

    More flexible than previously thought: Worms give us new insights into the evolution and diversification of TGF-β signaling pathways

    [ad_1]

    Newswise — Have you ever thought about what you have in common with tiny roundworms? As the “nematodes” are metazoan animals like we are, it is actually quite a lot. We have similar organ systems and what we learn from nematodes about gene function may be directly applicable to human development and disease. The best understood species is Caenorhabditis elegans and one of the many questions scientists investigate in this model species is “cellular signaling”, the way how molecules work together to control a cells function. A very important messenger protein or “cytokine” is the multifunctional Transforming growth factor-β (TGF-β) which is secreted by many cell types in both vertebrates and invertebrates. Through its complex signaling network it regulates gene expression and plays a crucial role throughout the lifetime of an animal for development, aging, metabolism and immunity. It is not surprising that a malfunction in these pathways can lead to severe pathologies like rheumatic or cardiovascular diseases or cancer and as such, interfering agents, like TGF-β inhibitors, are already used as therapeutics. Very recently, it was discovered that TGF-β also plays a crucial role in some severe COVID-19 infections, where a chronic immune reaction develops that is no longer directed against the virus itself, but rather against the patient’s own body.

    Striking variability in behavior and morphology

    Researchers of the Max Planck Institute for Neurobiology of Behavior – caesar (MPINB) in Bonn, the Max Planck Institute for Biology in Tübingen and the California State University now gained new insights into the evolution and the function of TGF-β signaling. They identified and compared the TGF-β genes across nine different nematode species which revealed surprising differences in the number of TGF-β genes across different species. The team next focused on the species Pristionchus pacificus which showed many variations in the number of TGF-β genes compared to other nematodes including C. elegans. By making mutations in numerous different parts of the signaling pathway using genetic tools like CRISPR/Cas9 they found that there were many unexpected changes in function between P. pacificus compared to C. elegans. They showed that the so-called DBL-1 pathway regulating body morphology appears highly conserved, whereas they found a striking variability in the function of the so-called DAF-7 pathway. This included important differences in development, environmental sensing and in the behaviors between these species.

    The researchers found that TGF-β signaling has a crucial impact on important phenotypes in P. pacificus. While C. elegans only feeds on bacteria, P. pacificus is an omnivore and is capable of predating on other nematode larvae. In addition, they have a kin-recognition system which protects their offspring from being eaten. This study showed that TGF-β signaling in P. pacificus is important for forming the mouth structures associated with predation and notably, also for establishing the kin signal to identify and protect their relatives. “Our findings show a previously unknown and surprising flexibility in the TGF-β signaling pathway across nematodes. We need to think outside of the box and explore signaling networks in other less typical model species to really understand their function, how they regulate behavioral differences between the species and how complex traits evolve.” says Dr. James Lightfoot who leads the research group “Genetics of Behavior” at the MPINB.

    New insights might help to control harmful parasites

    Infections with parasitic worms, Helminthiasis, is a worldwide problem for human and livestock health and resistance to existing anthelmintics are emerging. Importantly, free-living nematodes such as C. elegans and P. pacificus can offer important insights for understanding parasitic nematodes further as they share many similarities with their parasitic cousins. In particular, these free-living species are able to enter an alternative long lived and stress resistant developmental stage called the “dauer” form when they encounter adverse conditions and this has many similarities with the infective larvae of parasitic nematodes. As such, a lot of research has been focused on the dauer stage in C. elegans, and  TGF-β signaling has been found to be important for dauer formation. “In P. pacificus, we did not find the same effect. Our results suggest that the mechanism seen in C. elegans might not necessarily be the same in other nematodes.” says Dr. James Lightfoot. Understanding the so far unknown variability between different species is therefore important for the development of new therapeutic approaches against harmful parasites.

    [ad_2]

    Max-Planck-Institut fur Neurobiologie des Verhaltens – caesar

    Source link

  • Biobanco vivo de tecido mamário da Mayo Clinic desempenha papel importante em inovações de pesquisas

    Biobanco vivo de tecido mamário da Mayo Clinic desempenha papel importante em inovações de pesquisas

    [ad_1]

    Newswise — ROCHESTER, Minnesota — O biobanco vivo de tecido mamário da Mayo Clinic está ajudando pesquisadores a identificar as formas pelas quais as portadoras de determinados genes podem ter maior risco de câncer de mama. 

    Por exemplo, em um estudo recente, o biobanco mostrou a importância em entender a influência que o gene BRCA1 pode ter no aumento do risco de câncer de mama em mulheres portadoras de tal gene. A equipe da pesquisa usou amostras do biobanco para validar a descoberta, diz o Dr. Nagarajan Kannan, Ph.D., diretor do Laboratório de Biologia de Câncer e Células Tronco da Mayo Clinic. 

    Entender como o Biobanco Vivo de Tecido Mamário apoiou esse estudo significa entender a abrangência do seu propósito e o que o torna único. 

    “Em 2016, com o apoio de muitos colegas médicos e pesquisadores, eu fundei o biobanco para coletar tecidos de mulheres com uma mutação germinativa específica e que se submeteram a cirurgia de mama na Mayo Clinic Rochester”, diz o Dr. Kannan. 

    O biobanco agora coleta amostras em todos as instalações da Mayo Clinic e inclui qualquer gene associado ao aumento do risco de câncer de mama, ele acrescenta.  

    Na Mayo Clinic em Rochester, Minnesota, as amostras também incluem tecido mamário de cirurgias estéticas, incluindo tecido vivo mamário masculino.  

    “O acesso ao tecido vivo mamário masculino para estudar a origem do câncer de mama masculino tem sido um grande desafio, e nós resolvemos isso”, diz o Dr. Kannan. “Um em cada 100 casos de câncer de mama ocorre em homens, mas a glândula mamária masculina e o câncer de mama masculino ainda são pouco estudados. Nós queremos mudar isso usando o recurso único que desenvolvemos.” 

    As amostras de tecido mamário para o biobanco são coletadas no dia da cirurgia. Em seguida, elas são levadas para uma unidade central de processamento no laboratório do Dr. Kannan.  

    “O processo é bastante trabalhoso”, diz ele. “Cada amostra é coletada e processada prontamente, e leva mais de um dia e meio para gerar o que chamamos de ‘organoides de tecidos ricos em células-tronco epiteliais’. Essas são unidades de tecido que ainda possuem células-tronco autorrenováveis. Elas são criopreservadas e adicionadas ao banco. Há a possibilidade de danificar amostras durante as etapas de processamento devido a pequenos erros. Por isso, houve uma grande otimização da metodologia para simplificar esse processo.” 

    Muitos bolsistas de pesquisa, estagiários e tecnólogos contribuíram coletivamente com mais de 10.000 horas para coletar, processar e armazenar essas amostras ricas em células-tronco. 

    A especialidade de isolar o crescimento em células-tronco intactas é o motivo pelo qual o Dr. Kannan quis a palavra “vivo” no nome do biobanco. Mesmo os tecidos armazenados coletados em autópsias alguns dias após a morte geram células-tronco vivas. A morte da pessoas não extingue as células-tronco e células progenitoras do tecido mamário, e essas células são um recurso vital para a pesquisa. 

    Devido ao seu foco, o Biobanco Vivo de Tecido Mamário preenche uma lacuna específica de pesquisa.  

    “Estamos focados no tecido que não se tornou um tumor, porque queremos entender as vulnerabilidades celulares que aumentam o risco do câncer de mama”, diz o Dr. Kannan. “Nosso foco é entender os estágios iniciais do desenvolvimento do câncer de mama que normalmente não são apresentados na clínica”. 

    Atualmente, o biobanco conta com cerca de 500 amostras de pacientes. Cada amostra inclui uma pesquisa com cerca de 150 perguntas feitas aos participantes. A pesquisa fornece informações sobre outros fatores que podem contribuir para o risco elevado de câncer, como dieta, estilo de vida, genética e histórico familiar e médico. 

    Para obter mais informações, visite o site da Mayo Clinic Laboratories. 

    ###        

    Sobre a Mayo Clinic   A Mayo Clinicé uma organização sem fins lucrativos comprometida com a inovação na prática clínica, educação e pesquisa, fornecendo compaixão, conhecimento e respostas para todos que precisam de cura. Visite a Rede de Notícias da Mayo Clinicpara obter outras notícias da Mayo Clinic.   

    [ad_2]

    Mayo Clinic

    Source link

  • البنك الحيوي الحي للثدي في مايو كلينك يلعب دورًا رئيسيًا في إنجازات بحثية

    البنك الحيوي الحي للثدي في مايو كلينك يلعب دورًا رئيسيًا في إنجازات بحثية

    [ad_1]

    مدينة روتشستر، ولاية مينيسوتا. — يساعد البنك الحيوي الحي للثدي في مايو كلينك الباحثين في تحديد الطرق التي قد تزيد من احتمالية تعرض حاملي جينات معينة لخطر الإصابة بسرطان الثدي.

    [ad_2]

    Mayo Clinic

    Source link

  • Finding the right AI for you

    Finding the right AI for you

    [ad_1]

    Newswise — The human genome is three billion letters of code, and each person has millions of variations. While no human can realistically sift through all that code, computers can. Artificial intelligence (AI) programs can find patterns in the genome related to disease much faster than humans can. They also spot things that humans miss. Someday, AI-powered genome readers may even be able to predict the incidence of diseases from cancer to the common cold. Unfortunately, AI’s recent popularity surge has led to a bottleneck in innovation.

    “It’s like the Wild West right now. Everyone’s just doing whatever the hell they want,” says Cold Spring Harbor Laboratory (CSHL) Assistant Professor Peter Koo. Just like Frankenstein’s monster was a mix of different parts, AI researchers are constantly building new algorithms from various sources. And it’s difficult to judge whether their creations will be good or bad. After all, how can scientists judge “good” and “bad” when dealing with computations that are beyond human capabilities?

    That’s where GOPHER, the Koo lab’s newest invention, comes in. GOPHER (short for GenOmic Profile-model compreHensive EvaluatoR) is a new method that helps researchers identify the most efficient AI programs to analyze the genome. “We created a framework where you can compare the algorithms more systematically,” explains Ziqi Tang, a graduate student in Koo’s laboratory.

    GOPHER judges AI programs on several criteria: how well they learn the biology of our genome, how accurately they predict important patterns and features, their ability to handle background noise, and how interpretable their decisions are. “AI are these powerful algorithms that are solving questions for us,” says Tang. But, she notes: “One of the major issues with them is that we don’t know how they came up with these answers.”

    GOPHER helped Koo and his team dig up the parts of AI algorithms that drive reliability, performance, and accuracy. The findings help define the key building blocks for constructing the most efficient AI algorithms going forward. “We hope this will help people in the future who are new to the field,” says Shushan Toneyan, another graduate student at the Koo lab.

    Imagine feeling unwell and being able to determine exactly what’s wrong at the push of a button. AI could someday turn this science-fiction trope into a feature of every doctor’s office. Similar to video-streaming algorithms that learn users’ preferences based on their viewing history, AI programs may identify unique features of our genome that lead to individualized medicine and treatments. The Koo team hopes GOPHER will help optimize such AI algorithms so that we can trust they’re learning the right things for the right reasons. Toneyan says:  “If the algorithm is making predictions for the wrong reasons, they’re not going to be helpful.”

    [ad_2]

    Cold Spring Harbor Laboratory

    Source link

  • As the University of Idaho homicide investigation enters a critical stage, police must protect information ‘at all costs,’ experts say | CNN

    As the University of Idaho homicide investigation enters a critical stage, police must protect information ‘at all costs,’ experts say | CNN

    [ad_1]



    CNN
     — 

    The investigation into the murders of four University of Idaho students is entering a critical stage in its third week, as police are starting to receive forensic testing results from the crime scene, law enforcement experts tell CNN.

    Dozens of local, state and federal investigators have yet to identify a suspect or find the murder weapon used in the attack last month in Moscow.

    The public, as well as the victims’ family members, have criticized police for releasing little information, in what at times has been a confusing narrative.

    But the complex nature of a high-level homicide investigation involves utmost discretion from police, experts say, because any premature hint to the public about a suspect or the various leads police are following can cause it to fall apart.

    “What police have been reluctant to do in this case is to say they have a suspect, even though they have had suspects who have risen and fallen in various levels of importance, because that’s the nature of the beast,” said John Miller, CNN chief law enforcement analyst and former deputy commissioner of intelligence and counterterrorism for the New York Police Department.

    “Police having no suspects is factually incorrect,” Miller said. “Police have had a number of suspects they’ve looked at, but they have no suspect they’re willing to name. You don’t name them unless you have a purpose for that. That’s not unusual.”

    The victims – Ethan Chapin, 20; Kaylee Goncalves, 21; Xana Kernodle, 20; and Madison Mogen, 21 – were found stabbed on the second and third floors of their shared off-campus home on November 13, according to authorities.

    The quadruple murder has upended the town of 26,000 residents, which had not recorded a single murder since 2015, and challenged a police department which has not benefited from the experience of investigating many homicides, let alone under the pressure of a national audience, Miller says.

    The Moscow Police Department is leading the investigation with assistance from the Idaho State Police, the Latah County Sheriff’s Office and the FBI, which has assigned more than 40 agents to the case across the United States.

    “They have really coordinated this into over 100 people that are operating as one team,” Miller said of the homicide investigation.

    The FBI plays three important roles in the Idaho investigation, according to Miller.

    The first involves its behavioral science unit, which is highly valuable for cases with an unknown offender because it narrows the scope of offender characteristics.

    The second is its advanced technology, such as its Combined DNA Indexing System, which allows law enforcement officials and crime labs to share and search through thousands of DNA profiles.

    Lastly, the FBI has 56 field offices in major cities throughout the country, which can expand the reach and capability of the investigation.

    “The FBI brings a lot to this, as well as experience in a range of cases that would be beyond what a small town typically would have,” Miller said.

    Every homicide investigation begins with the scene of the crime, which allows investigators only one chance to record and collect forensic evidence for processing, which includes toxicology reports on the victims, hair, fibers, blood and DNA, law enforcement experts say.

    “That one chance with the crime scene is where a lot of opportunities can be made or lost,” Miller said.

    Extensive evidence has been collected over the course of the investigation, including 113 pieces of physical evidence, about 4,000 photos of the crime scene and several 3D scans of the home, Moscow police said Thursday.

    “To protect the investigation’s integrity, specific results will not be released,” police said.

    Latah County Coroner Cathy Mabbutt told CNN she saw “lots of blood on the wall” when she arrived at the scene and police said “some” of the victims had defensive wounds.

    Chances are “pretty high” a suspect could have cut themselves during the attack, so police are looking carefully at blood evidence, says Joe Giacalone, adjunct professor at John Jay College of Criminal Justice and retired NYPD sergeant who directed the agency’s Homicide School and Cold Case Squad.

    Lab results from the scene can be returned to investigators fairly quickly, but in this case investigators are dealing with mixtures of DNA, which can take longer, he says.

    “When you have several donors with the DNA, then it becomes a problem trying to separate those two or three or four. That could be part of the issue … toxicology reports can sometimes take a couple of weeks to come back,” Giacalone added.

    The next stage in a homicide investigation is looking at the behavioral aspects of the crime. Two agents with the FBI’s Behavior Analysis Unit were assigned to the case to assess the scene and go over evidence to learn about the suspect or suspects’ behavior, based on the way they carried out the crime, Miller says.

    “Understanding the victimology in a mystery can be very important, because it can lead you to motivation, it can lead you to enemies and it can lead you to friends,” he said.

    Investigators will learn every detail about the four victims, their relationships with each other and the various people in their lives, Miller says. This includes cell phone records and internet records, he says, as well as video surveillance from every camera surrounding the crime scene.

    “When you do an extensive video canvass, you may get a picture of a person, a shadowy figure, and then if you have a sense of direction, you can string your way down all the other cameras in that direction to see if that image reappears,” Miller said.

    At this stage, investigators rely on the FBI’s Violent Criminal Apprehension Program, which collects and analyzes information about violent crimes in the United States.

    The program can match a suspect’s DNA found at the scene with that of a person who is already in the system. It also scans all crimes across the country to determine if the way the attack was carried out mirrors a previous one, pointing to the same perpetrator, Miller says.

    “You always start with people who are close to the victims, whether it’s love, money or drugs,” Giacalone told CNN. “That’s generally the first step that you take because most of us are victimized by someone we know. We have to ask things like, who would benefit from having this person or in this case, a group, killed?”

    In an effort to locate the weapon – believed to be a fixed-blade knife – detectives contacted local businesses to see if a similar knife had been purchased recently.

    “It’s highly unlikely, although not impossible, that a first-time offender is going to come prepared with a tactical knife and murder multiple people, even in the face of resistance, and that this is going to be their first encounter with violent crime or the use of a knife,” Miller said.

    One aspect of a homicide investigation is to “keep the media happy,” according to Giacalone.

    “Today in the social media, true crime, community-driven world in these cases, the demand for information is so great that sometimes police departments kind of fill in that blank air and say something just for the sake of saying something, and then realizing that it’s either not 100% true, or it’s misleading,” he said.

    It’s critical for police to protect their information at “all costs” and they always know more than what they release to the public. Otherwise, it could cause the suspect to go on the run, he says.

    The media gathers as Moscow Police Chief James Fry speaks during a news conference.

    Miller said it’s “not fair” to investigators for the public or media to criticize them for not releasing enough information about the case.

    But, ultimately, the department has a moral obligation to share some information with families who are suffering in uncertainty, Miller says, but they must be judicious about what they share.

    “If you tell them we have a suspect and we’re close to an arrest but that doesn’t come together, then everybody is disappointed or thinks you messed it up or worse, goes out and figures out who the suspect is and tries to take action on their own,” he said.

    Investigators rely on the trove of physical and scientific evidence, information from the public and national data on violent crimes to cultivate possible leads, Miller says.

    Public tips, photos and videos of the night the students died, including more than 260 digital media submissions people have submitted through an FBI form, are being analyzed, police say. Authorities have processed more than 1,000 tips and conducted at least 150 interviews to advance the case.

    “Any one of those tips can be the missing link,” Miller said. “It can either be the connective tissue to a lead you already had but were missing a piece, or it can become the brand new lead that solves the case.”

    Every tip must be recorded in a searchable database so investigators can go back to them as they learn new details over the course of the investigation, Miller says. While 95% to 99% of public tips may provide no value, one or several might crack the entire case, he adds.

    “Police in this case could be nowhere tonight, having washed out another suspect, and tomorrow morning they could be making an arrest,” Miller said of the Idaho investigation. “Or, for the suspect they’re working on today, it might take them another month from now to put together enough evidence to have probable cause. That’s just something they won’t be able to reveal until it happens.”

    [ad_2]

    Source link

  • Human evolution wasn’t just the sheet music, but how it was played

    Human evolution wasn’t just the sheet music, but how it was played

    [ad_1]

    Newswise — DURHAM, N.C. — A team of Duke researchers has identified a group of human DNA sequences driving changes in brain development, digestion and immunity that seem to have evolved rapidly after our family line split from that of the chimpanzees, but before we split with the Neanderthals.

    Our brains are bigger, and are guts are shorter than our ape peers.

    “A lot of the traits that we think of as uniquely human, and human-specific, probably appear during that time period,” in the 7.5 million years since the split with the common ancestor we share with the chimpanzee, said Craig Lowe, Ph.D., an assistant professor of molecular genetics and microbiology in the Duke School of Medicine.

    Specifically, the DNA sequences in question, which the researchers have dubbed Human Ancestor Quickly Evolved Regions (HAQERS), pronounced like hackers, regulate genes. They are the switches that tell nearby genes when to turn on and off. The findings appear Nov.23 in the journal CELL.

    The rapid evolution of these regions of the genome seems to have served as a fine-tuning of regulatory control, Lowe said. More switches were added to the human operating system as sequences developed into regulatory regions, and they were more finely tuned to adapt to environmental or developmental cues. By and large, those changes were advantageous to our species.

    “They seem especially specific in causing genes to turn on, we think just in certain cell types at certain times of development, or even genes that turn on when the environment changes in some way,” Lowe said.

    A lot of this genomic innovation was found in brain development and the GI tract. “We see lots of regulatory elements that are turning on in these tissues,” Lowe said. “These are the tissues where humans are refining which genes are expressed and at what level.”

    Today, our brains are larger than other apes, and our guts are shorter. “People have hypothesized that those two are even linked, because they are two really expensive metabolic tissues to have around,” Lowe said. “I think what we’re seeing is that there wasn’t really one mutation that gave you a large brain and one mutation that really struck the gut, it was probably many of these small changes over time.”

    To produce the new findings, Lowe’s lab collaborated with Duke colleagues Tim Reddy, an associate professor of biostatistics and bioinformatics, and Debra Silver, an associate professor of molecular genetics and microbiology to tap their expertise. Reddy’s lab is capable of looking at millions of genetic switches at once and Silver is watching switches in action in developing mouse brains.

    “Our contribution was, if we could bring both of those technologies together, then we could look at hundreds of switches in this sort of complex developing tissue, which you can’t really get from a cell line,” Lowe said.

    “We wanted to identify switches that were totally new in humans,” Lowe said. Computationally, they were able to infer what the human-chimp ancestor’s DNA would have been like, as well as the extinct Neanderthal and Denisovan lineages. The researchers were able to compare the genome sequences of these other post-chimpanzee relatives thanks to databases created from the pioneering work of 2022 Nobel laureate Svante Pääbo.

    “So, we know the Neanderthal sequence, but let’s test that Neanderthal sequence and see if it can really turn on genes or not,” which they did dozens of times.

    “And we showed that, whoa, this really is a switch that turns on and off genes,” Lowe said. “It was really fun to see that new gene regulation came from totally new switches, rather than just sort of rewiring switches that already existed.” 

    Along with the positive traits that HAQERs gave humans, they can also be implicated in some diseases.

    Most of us have remarkably similar HAQER sequences, but there are some variances, “and we were able to show that those variants tend to correlate with certain diseases,” Lowe said, namely hypertension, neuroblastoma, unipolar depression, bipolar depression and schizophrenia. The mechanisms of action aren’t known yet, and more research will have to be done in these areas, Lowe said.

    “Maybe human-specific diseases or human-specific susceptibilities to these diseases are going to be preferentially mapped back to these new genetic switches that only exist in humans,” Lowe said.

    Support for the research came from National Human Genome Research Institute – NIH (R35-HG011332), North Carolina Biotechnology Center (2016-IDG-1013, 2020-IIG-2109), Sigma Xi, The Triangle Center for Evolutionary Medicine and the Duke Whitehead Scholarship.

    CITATION: “Adaptive Sequence Divergence Forged New Neurodevelopmental Enhancers in Humans,” Riley J. Mangan, Fernando C. Alsina, Federica Mosti, Jesus Emiliano Sotelo-Fonseca, Daniel A. Snellings, Eric H. Au, Juliana Carvalho, Laya Sathyan, Graham D. Johnson, Timothy E. Reddy, Debra L. Silver, Craig B. Lowe. CELL, Nov. 23, 2022. DOI: 10.1016/j.cell.2022.10.016

    [ad_2]

    Duke University

    Source link

  • Protein spheres protect the genome of cancer cells

    Protein spheres protect the genome of cancer cells

    [ad_1]

    Newswise — MYC genes and their proteins play a central role in the emergence and development of almost all cancers. They drive the uncontrolled growth and altered metabolism of tumour cells. And they help tumours hide from the immune system.

    MYC proteins also show an activity that was previously unknown – and which is now opening new doors for cancer research: They form hollow spheres that protect particularly sensitive parts of the genome. If these MYC spheres are destroyed, cancer cells will die.

    This was reported by a research team led by Martin Eilers and Elmar Wolf from the Institute of Biochemistry and Molecular Biology at Julius-Maximilians-Universität Würzburg (JMU, Bavaria, Germany) in the journal “Nature”. The researchers are convinced that their discovery is a game changer for cancer research, an important breakthrough on the way to new therapeutic strategies.

    Hollow spheres protect sensitive DNA sites

    What the researchers discovered: When cells in the lab are kept under stress conditions similar to those found in fast-growing tumour cells, the MYC proteins in the cell nucleus rearrange themselves in a dramatic way. They join together to form hollow spheres consisting of thousands of MYC proteins.

    The hollow spheres surround and protect individual, particularly sensitive sites in the genome – precisely the sites where two types of enzymes can collide: Enzymes that read DNA to synthesize RNA and enzymes that duplicate DNA. Both can be thought of as two trains travelling on only one track, on DNA.

    The hollow spheres thus prevent the two enzymes from colliding. The Würzburg team was able to confirm this observation in cancer cells. If the protective function of the protein spheres is switched off experimentally, collisions of the enzymes occur and, as a consequence, multiple breaks occur in the DNA – which ultimately kill the cancer cells.

    Search for specifically effective drugs

    “These observations revolutionize our understanding of why MYC proteins are so crucial for the growth of tumor cells,” says Martin Eilers. The new findings also raise the question of whether drugs can be developed that specifically prevent the formation of the hollow spheres.

    To drive this development forward, Eilers and Wolf have started a company. Together with JMU and partners from the pharmaceutical industry, the search for drugs that interfere with the newly discovered functions of the MYC proteins has begun.

    “The fact that investors made it possible for us to set up so quickly is certainly not an everyday occurrence,” say the JMU professors. They also consider this as a sign that they have made a discovery that is very promising.

    [ad_2]

    University of Wurzburg

    Source link

  • Genome studies uncover a new branch in fungal evolution

    Genome studies uncover a new branch in fungal evolution

    [ad_1]

    Newswise — About 600 seemingly disparate fungi that never quite found a fit along the fungal family tree have been shown to have a common ancestor, according to a University of Alberta-led research team that used genome sequencing to give these peculiar creatures their own classification home.

    “They don’t have any particular feature that you can see with the naked eye where you can say they belong to the same group. But when you go to the genome, suddenly this emerges,” says Toby Spribille, principal investigator on the project and associate professor in the Department of Biological Sciences.

    “I like to think of these as the platypus and echidna of the fungal world.”

    Spribille, Canada Research Chair in Symbiosis, is referring to Australia’s famed Linnaean classification system-defying monotremes — which produce milk and have nipples, but lay eggs — that were the source of debate as to whether they were even real.

    “Though nobody thought our fungi were fake, it’s similar because they all look totally different.”

    Using DNA-based dating techniques, the team found that this new class of fungi, called Lichinomycetes, descended from a single origin 300 million years ago, or 240 million years before the extinction of dinosaurs. 

    David Díaz-Escandón, who performed the research as part of his PhD thesis, explains that these “oddball” fungi were previously sprinkled across seven different classes — a high-level grouping that in animals would be equivalent to the groups called mammals or reptiles. 

    Working with a team of researchers from seven countries to get material from the fungi, he sequenced 30 genomes and found that all classes but one descended from a single origin.

    “They were classified, but they were classified into such different parts of the fungal side of the tree of life that people never suspected they were related to each other,”  says Díaz-Escandón. 

    These fungi include forms as varied as earth tongues — eerie tongue-shaped fungi that shoot up vertically out of the ground — beetle gut microbes, and a fungus found in tree sap in northern Alberta. They also include some unusual lichens that survive in extreme habitats such as South America’s Atacama Desert, the driest non-polar desert in the world.

    “What is really fascinating is that despite these fungi looking so different, they have a lot in common at the level of their genomes,” says Spribille. “Nobody saw this coming.”

    Based on their genomes, which are small compared with those of other fungi, the team predicts that this group of fungi depend on other organisms for life.

    “Their small genomes mean this class of fungi have lost much of their ability to integrate some complex carbohydrates,” said Spribille. “When we go back to look at each of these fungi, suddenly we see all of them are in a kind of symbiosis.”

    He notes the new research will be important to the broader study of fungal evolution, specifically how fungi inherit important biotechnological features such as enzymes that break down plant matter.

    The new group also could be a source of new information about past fungal extinctions. 

    “We think it’s likely that the diversity we see today is just the tip of the iceberg that survived. And we don’t have that many examples of this kind of thing in fungi.”

    The research appears online in the journal Current Biology.

    [ad_2]

    University of Alberta

    Source link

  • Gene that guides earliest social behaviors could be key to understanding autism

    Gene that guides earliest social behaviors could be key to understanding autism

    [ad_1]

    Newswise — Little is known about how social behavior develops in the earliest stages of life. But most animals––including humans––are born with an innate ability to interact socially or form bonds with others. And that contributes to success throughout life.

    Now, a new animal study points to a gene that is important for the earliest development of basic social behaviors.

    The work also suggests that exposure to certain drugs and environmental risk factors during embryonic development can cause changes to this gene, leading to alterations in social behavior that are similar to those found in individuals who have autism. Much to their surprise, the researchers also found they could reverse some of the effects using an experimental drug.

    “This study helps us understand at the molecular level why sociability is disrupted during the very earliest stages of life,” says Randall T. Peterson, Ph.D., the corresponding author of the study and dean of the University of Utah College of Pharmacy. “It also gives us an opportunity to explore potential treatments that could restore sociability in these animals and, perhaps in time, eventually in humans as well.”

    More broadly, their findings suggest that the gene—TOP2a—controls a large network of genes that are known to increase the risk of autism. It also may serve as a link between genetic and environmental factors that contribute to onset of disorder, Peterson adds.

    The study, conducted by University of Utah Health researchers and colleagues nationwide, appears in the Nov. 23 issue of Science Advances.

    Anti-social animals

    Scientists suspect many social traits are determined before birth. But the precise mechanisms involved in this process remain murky. One promising area of research suggests that social behavior and other characteristics and traits are influenced not only by our genetic makeup but also how and where we live. 

    To test this model, the scientists evaluated whether environmental exposures during embryonic development could influence social behavior. Peterson and his colleagues exposed zebrafish embryos to more than 1,100 known drugs––one drug per 20 embryos––for 72 hours beginning three days after conception.

    The researchers determined that four of the 1,120 tested drugs significantly reduced sociability among the zebrafish. Fish exposed to these drugs were less likely to interact with other fish. It turned out that the four medications all belonged to the same class of antibiotics, called fluoroquinolones. These drugs are used to treat upper and lower respiratory tract infections in people.

    When the scientists gave a related drug to pregnant mice, the offspring behaved differently when they became adults. Even though they appeared normal, they communicated less with other mice and engaged in more repetitive acts—like repeatedly poking their head in the same hole—than other rodents.

    A basis for sociability

    Digging deeper, the researchers found that the drugs suppressed a gene called TOP2a, which, in turn, acted on a cluster of genes that are known to be involved in autism in humans.

    They also found that the cluster of autism-associated genes shared another thing in common—a higher than usual tendency to bind a group of proteins called the PRC2.  The researchers hypothesized that Top2a and the PRC2 work together to control the production of many autism-associated genes.

    To determine whether the anti-social behaviors could be reversed, the research team gave embryonic and young zebrafish an experimental drug called UNC1999, which is known to inhibit the PRC2. After treatment with the drug, fish exposed to fluoroquinolones were more likely to swim closer to other fish, demonstrating that the drug helped restore sociability. They saw similar results with other drugs known to inhibit the same key gene, TOP2a. 

    “That really surprised me because I would’ve thought disrupting brain development when you’re an embryo would be irreversible,” Peterson says. “If you don’t develop sociality as an embryo, you’ve missed the window. But this study suggests that even in those individuals later in life, you can still come in and inhibit this pathway and restore sociality.”

    Moving forward, the researchers plan to explore how and why this drug had this effect.

    Although the scientists only found four compounds that are Top2a inhibitors, evidence suggests hundreds of other drugs and naturally occurring compounds in our environment can inhibit its activity.

    “It’s possible that these four compounds are just the tip of the iceberg in terms of substances that could be problematic for embryonic exposure,” Peterson says.

    However, Peterson notes that this study was conducted in animals, and more research needs to be done before any of its results can be confirmed in humans. Therefore, he cautions against drawing conclusions about real-world applications.

    “We have no evidence that fluroquinolones or any other antibiotic causes autism in humans,” Peterson says. “So, there is no reason to stop using antibiotics. What this paper does identify is a new molecular pathway that appears to control social development and is worthy of further exploration.”

                                                    ###

    In addition to Dr. Peterson, U of U Health scientists Yijie Geng, Tejia Zhang, Ivy G. Alonzo, Sean C. Godar, Christopher Yates, Brock Plummer, and Marco Bortolato contributed to this study. Other participating institutions include the University of Chicago; Beth Israel Deaconess Medical Center in Boston; Massachusetts General Hospital and Harvard Medical School; the Broad Institute, Cambridge, Massachusetts; and MDI Biological Laboratory, Bar Harbor, Maine.

    The study, “Top2a promotes the development of social behavior via PRC2 and H3K27me3,” appears in the Nov. 23, 2022, issue of Science Advances. This research was supported by the L. S. Skaggs Presidential Endowed Chair and the National Institute of Environmental Health Sciences at the National Institutes of Health.

    [ad_2]

    University of Utah Health

    Source link

  • Pesquisadores investigam a nutrição de precisão para melhorar a saúde e prevenir doenças 

    Pesquisadores investigam a nutrição de precisão para melhorar a saúde e prevenir doenças 

    [ad_1]

    Newswise — ROCHESTER, Minnesota A prescrição de determinados nutrientes, grãos, frutas e legumes personalizados para os genes e outras características biológicas de uma pessoa pode ajudar a melhorar sua saúde? Os pesquisadores da Mayo Clinic estão explorando os possíveis benefícios da orientação personalizada de dieta e de nutrientes para os genes, o metabolismo, o microbioma e outras características distintas de uma pessoa. O objetivo final dessa abordagem abrangente é promover saúde e ajudar a prevenir doenças relacionadas à alimentação, incluindo doença cardíaca, diabetes e alguns cânceres. 

    A pesquisa mostra que cerca de 11 milhões de mortes por ano em todo o mundo estão ligadas a fatores relacionados à alimentação, juntamente com os impactos contribuintes da genética, idade, sexo, peso e deficiências no sono e no exercício. 

    Assim como as pessoas têm respostas diferentes a determinados medicamentos, fator que é conhecido como farmacogenômica, os genes e o estilo de vida de uma pessoa também podem alterar a resposta aos alimentos que ela ingere, incluindo como o corpo metaboliza, absorve e distribui os nutrientes. 

    A nutrição de precisão faz parte de uma nova era na medicina individualizada, orientada pelo avanço nas abordagens multiômicas, com atenção especial à metabolômica, que é o estudo das substâncias criadas quando o corpo metaboliza alimentos, medicamentos ou o próprio tecido. 

    A multiômica é uma combinação de duas ou mais abordagens “ômicas”. Relacionada à nutrição, uma abordagem multiômica combinada usa a genômica, a metabolômica e o microbioma do paciente. Outras abordagens “ômicas” incluem a proteômica (o estudo das proteínas), a epigenômica (o estudo das mudanças epigenéticas no DNA) e a transcriptômica (o estudo das moléculas de RNA). 

    O Dr. Ian Lanza, Ph.D., dirige um programa de pesquisa em endocrinologia, nutrição e metabolismo, e é o diretor da Unidade Principal de Metabolômica da Mayo Clinic, especializada como um recurso analítico para detecção e quantificação de pequenas moléculas. A pesquisa do Dr. Lanza é centralizada na obesidade, no envelhecimento e em outras disfunções relacionadas ao metabolismo. 

    “No geral, meu trabalho está focado em descobrir abordagens eficazes, realistas e econômicas para ajudar as pessoas a viver vidas mais saudáveis por mais tempo, avançando no entendimento dos eventos celulares moleculares que contribuem para o declínio metabólico e funcional”, diz o Dr. Lanza. “As tecnologias metabolômicas podem nos ajudar a detectar e quantificar as várias moléculas pequenas que estão em todas as nossas células. Elas estão na nossa corrente sanguínea. Estão na urina, na saliva e nas lágrimas.” 

    O Dr. Lanza diz que analisar pequenas moléculas pode oferecer uma visão do que está acontecendo com determinadas vias metabólicas em uma célula. 

    “A metabolômica nos ajuda a responder a perguntas como: quais vias metabólicas subjacentes podem ser alteradas por uma doença ou um tratamento e quem pode desenvolver uma doença futura?”, explica o Dr. Lanza. 

    O Dr. Lanza diz que o poder da metabolômica é a possibilidade de conseguir prever o risco de uma pessoa para certas doenças e oferecer oportunidades de prevenção. 

    Para saber mais informações, visite o Centro de Medicina Individualizada da Mayo Clinic 

    ### 

    Sobre a Mayo Clinic   

    A Mayo Clinic é uma organização sem fins lucrativos comprometida com a inovação na prática clínica, educação e pesquisa, fornecendo compaixão, conhecimento e respostas para todos que precisam de cura. Visite a Rede de Notícias da Mayo Clinic para obter outras notícias da Mayo Clinic. 

       

    [ad_2]

    Mayo Clinic

    Source link

  • 研究人员调查精准营养以改善健康和预防疾病 

    研究人员调查精准营养以改善健康和预防疾病 

    [ad_1]

    罗切斯特,明尼苏达州 — 如果根据一个人的基因和其他生物学特征来制定包含特定营养物质、谷物、水果和蔬菜的专门食谱,是否有助于改善他们的健康状况?妙佑医疗国际(Mayo Clinic) 的研究人员正在探索根据一个人的基因、新陈代谢、微生物群系和其他区别特征来定制营养物质和膳食指南的潜在益处。这种综合方法的最终目标是改善健康,帮助预防与饮食相关的疾病,包括心脏病、糖尿病和某些癌症。

    [ad_2]

    Mayo Clinic

    Source link

  • Type 2 diabetes genes linked with gestational diabetes in South Asian women

    Type 2 diabetes genes linked with gestational diabetes in South Asian women

    [ad_1]

    Newswise — The same complex genetics that contribute to a higher risk of type 2 diabetes may also increase the risk of developing diabetes during pregnancy among women of South Asian descent, a study published today in eLife shows. 

    The discovery may lead to new ways to identify women who would benefit from interventions to prevent diabetes during pregnancy.  

    People of South Asian descent have an elevated risk of developing type 2 diabetes. Women in this group are also twice as likely to develop a condition called gestational diabetes during pregnancy than women of European descent. But why South Asians are at an increased risk of these two conditions is not currently clear.

    “Only a handful of studies have looked at how genetic and environmental factors interact in gestational diabetes in South Asian women,” says lead author Amel Lamri, a research associate at McMaster University and Population Health Research Institute (PHRI) in Ontario, Canada. “None have looked at how the genes associated with type 2 diabetes may interact with environmental factors to contribute to gestational diabetes in South Asian women.” 

    To close this gap, Lamri and colleagues assessed the relationship between genes associated with type 2 diabetes, environmental factors, and gestational diabetes. They examined whether having genetic signatures linked with type 2 diabetes risk is also connected with gestational diabetes in 837 and 4,372 South Asian women who participated in the SouTh Asian BiRth CohorT (START) study, and the Born in Bradford (BiB) study respectively. 

    The team measured the genetic risk of type 2 diabetes using a polygenic risk score, which estimates the hereditary risk of an individual developing a disease based on the number of risk alleles they have. The researchers found that South Asian women with higher type 2 diabetes polygenic risk scores also had a higher risk of gestational diabetes; each incremental increase in the score was associated with a 45% increase in the risk of developing this condition. 

    When the scientists studied the gestational diabetes risk at the population level, they found that having a polygenic risk score in the highest one-third explained 12.5% of the risk of developing this condition in South Asian women. When they combined a family history of type 2 diabetes and having a polygenic risk score in the top third, it explained 25% of the risk of developing gestational diabetes.  

    “These results show that a higher type 2 diabetes polygenic risk score and a family history of diabetes are strongly and independently associated with gestational diabetes in women of South Asian descent,” explains Lamri. 

    The scientists also looked at whether environmental factors modulated these genetic risk factors. Most of the environmental factors they considered (with the possible exception of body mass index and diet quality) did not significantly alter the risk of diabetes during pregnancy in both studies. But the authors note that the studies may not have been large enough to detect more modest environmental effects, and that further studies are needed in order to confirm the modulatory effects they observed . 

    “Our results support the idea that type 2 diabetes and gestational diabetes share a common genetic background,” concludes senior author Sonia Anand, the Michael G. DeGroote Chair in Population Health, and a senior scientist at PHRI, McMaster University, and Hamilton Health Sciences. “If future studies confirm our results, this information may help identify which women would benefit most from interventions to help prevent diabetes during pregnancy.” 

    ##

     

    About eLife

    eLife transforms research communication to create a future where a diverse, global community of scientists and researchers produces open and trusted results for the benefit of all. Independent, not-for-profit and supported by funders, we improve the way science is practised and shared. From the research we publish, to the tools we build, to the people we work with, we’ve earned a reputation for quality, integrity and the flexibility to bring about real change. eLife receives financial support and strategic guidance from the Howard Hughes Medical InstituteKnut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.

    To read the latest Genetics and Genomics research published in eLife, visit https://elifesciences.org/subjects/genetics-genomics.

    [ad_2]

    eLife

    Source link

  • How Genetics Are Involved

    How Genetics Are Involved

    [ad_1]

    Inherited retinal dystrophies are disorders passed down through families. Learn how this affects which one you may have, diagnosis, and possible treatment.

    [ad_2]

    Source link

  • Talking to Your Kids

    Talking to Your Kids

    [ad_1]

    There’s a lot to think about when you find out that you have autosomal dominant polycystic kidney disease (ADPKD).

    When do you start treatment?

    Will your daily life change?

    How will it affect your kids?

    That last one can be really tough. But Jillian Warejko, MD, a pediatric kidney specialist at Yale Medicine, says it’s important for kids to learn what to expect.

    “There’s a lot of power in knowing your own health history,” Warejko says. “So we try to teach kids to empower themselves and advocate for themselves.”

    You should tailor your conversation based on your child’s developmental age. And you may want to space your talks out over time.

    Here are some topics to get you started. 

    How You Get It

    If your kids are teenagers or young adults, you can break down the basics of this autosomal dominant genetic disease. Warejko explains that a faulty gene on a non-sex chromosome causes ADPKD. That means that whether your child is male or female, there’s a 50% chance they’ll get this mutated gene from you. And if they have the disease, there’s a 50% chance they’ll pass it on to their kids.

    You may need to give younger kids less information. You can still bring up ADPKD. But use age-appropriate terms that aren’t scary.

    “You don’t want kids to be fearful,” Warejko says. “Fear can make people not want to go to the doctor.” 

    In her practice, Warejko describes ADPKD like this:

    “It sounds like a couple of family members have had this illness called kidney disease. And the reason you’re visiting with me today is because we want to make sure that, if you have kidney disease too, we’re doing everything in our power to make sure you stay as healthy as possible.”

    She also tells kids that it’s best to treat this disease early, when their kidneys are “good” and still work like normal. And the best way to do that, she says, is to “make sure that you’re checking in with us.”

    Symptoms to Watch For

    If your kids have ADPKD, they might not have any problems when they’re children or young adults.

    “The disease can be relatively quiet in those early years,” says Neera Dahl, MD, PhD, a kidney specialist with Yale Medicine.

    With that said, Dahl thinks parents and kids should know what to watch for.

    Tell your child to speak up if they notice:

    • Back or side pain
    • Blood or pain when they pee
    • Any other urine changes 
    • Frequent headaches

    Encourage your kids to keep track of their health details.

    “If the doctor tells them their blood pressure is a little high, take down that number,” Warejko says. “Everyone has a piece of ‘paper’ wherever they go because our phones have ‘notes.’”

    You can also share what the disease feels like for you. But keep in mind that your child may not have the same experience.

    “The tricky thing about ADPKD is that everyone is a little bit different, even among family members,” Warejko says. “But I always encourage families to be open with one another.”

    When and How to Get Diagnosed

    Children may only need regular wellness visits once a year. But their doctor should check for high blood pressure or blood in the urine.

    “If those are off, that’s a reason to investigate further,” Dahl says. “Otherwise, it’s OK to monitor kids to see how they’re doing.”

    Warejko stresses the importance of annual checkups throughout the late teens and early 20s. Sometimes young adults who might have ADPKD skip these screening tests, she says, because they feel healthy. Though they could have high blood pressure or cysts and not know it.

    “One of the hardest parts about kidney disease is you don’t feel it until you feel it,” she says.   

    To diagnose ADPKD, you may get:

    Imaging tests. The most common one is an ultrasound, Dahl says. It’s a painless test that can take pictures of the urinary tract or kidneys. Other imaging tests include a computed tomography (CT) scan or magnetic resonance imaging (MRI). 

    Genetic testing. This is a surefire way to know if you have ADPKD. But it might not be the right choice for everyone, especially young kids. “There’s a lot of debate about what it means to genetically test someone who’s under the age of 18, when they’re not at an age that they can fully consent,” Warejko says. “Not every person wants to know what their genetic predisposition is.”

    Ask your doctor to refer you to a genetic counselor. They can help you figure out if this is something you or your family might want to do.

    Pre-implantation screening. This is for your adult kids who want to start a family. People who use in vitro fertilization (IVF) can get a special test to check for ADPKD in fertilized eggs. It’s not 100% accurate. But it can be a choice for people who want to take steps to lower the odds that they’ll pass on the gene, Dahl says.

    Set a Good Example

    You can teach your kids some healthy habits to protect their kidneys. If they ask why, tell them you want to help them achieve their goals. That’s what Warejko does. She asks kids what they want to be when they grow up. Then she tells them, “I want you to be successful, and part of that is being healthy.”

    Her tips include:

    • Drink plenty of water.
    • Eat a low-salt diet.
    • Get enough physical activity.
    • Eat lots of fresh fruits and vegetables.
    • Avoid processed and fast foods.

    Warejko knows it’s not easy for everyone to make these healthy changes. Some families may not have access to fresh produce or live in a neighborhood where it’s safe to go for walks. That’s why she makes an effort to brainstorm with kids and parents. She’ll help them find ways to get healthy food or exercise in their home. “I try to specifically ask, ‘What are the restrictions we need to work inside?’”

    Life With ADPKD

    Treatment has come a long way in recent years.  In 2018, the FDA approved tolvaptan (Jynarque), the first drug to treat adults with ADPKD. It can slow down cyst formation on the kidneys.

    “I think tolvaptan is going to change the trajectory and we’re not going to see as many people ending up with kidney failure,” Warejko says. “My hope is that snowball will continue to roll downhill.”

    [ad_2]

    Source link

  • UC San Diego Awarded $8M to Expand Stem Cell Therapy Clinical Trials

    UC San Diego Awarded $8M to Expand Stem Cell Therapy Clinical Trials

    [ad_1]

    Newswise — Stem cells show particular promise in treating diseases for which few other effective treatments exist. In these therapies, stem cells are introduced into the body where they develop into specialized cells that repair, restore, replace or regenerate cells that have been damaged by the disease.

    As part of a state-wide effort to advance stem cell therapies, the California Institute for Regenerative Medicine (CIRM) has awarded $8 million to the UC San Diego Alpha Stem Cell Clinic. The funding will support the clinic’s mission of bringing new stem cell-based therapies to patients with difficult-to-treat diseases.

    The Alpha Clinics — named for being the first of their kind — are a network of clinics spanning the state of California, designed to bridge the gap between stem cell research and clinical application. The system brings together clinical, research, regulatory and administrative teams in order to expedite clinical trials and streamline the patient experience.

    “We’re trying to change the way we do medicine,” said Catriona Jamieson, MD, PhD, director of the UC San Diego Alpha Stem Cell Clinic and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine. “The Alpha Clinic helps academic and industry experts join forces to bring world-class technologies directly to the patients.”

    The grant is part of a series of recent CIRM awards totaling $72 million to expand the Alpha Clinics network. UC San Diego was one of three founding institutions when the project launched in 2015. The new funding will expand the program to nine sites across the state.

    In the seven years since its inception, the UC San Diego Alpha Stem Cell Clinic has launched 59 clinical trials and treated 277 patients with new therapies for neurodegeneration, diabetes and various forms of cancer. The trials largely test cell, gene and immunotherapies developed through growing partnerships between UC San Diego and local biotechnology and pharmaceutical companies.

    Recent milestones include the completion of a Phase I trial using neural stem cells to treat spinal cord injury, in which patients showed improved motor function after the treatment, as well as approval from the U.S. Food and Drug Administration (FDA) for a Phase III registration trial of a blood cancer stem cell-targeting monoclonal antibody.

    The latest funding will help expand clinical trials at both La Jolla and Hillcrest Medical Centers and create a Clinical Fellowship Program to educate additional physicians in advanced regenerative medicine therapies.

    Another major goal of the clinic is to improve accessibility and awareness of stem cell science. A portion of the funding will go towards new patient education programs and efforts to make treatments more accessible to historically underserved communities in San Diego and Imperial Counties.

    “Patients come to us when nothing else has worked, so we are thrilled to be able to provide new treatments to our community that are not available in other parts of the country,” said Jamieson. “The Alpha Clinics’ highly collaborative infrastructure will help us develop and validate high-quality stem cell therapies at an unprecedented speed, and the effects will be seen across California and beyond.”

    Funding for the UC San Diego Alpha Stem Cell Clinic comes from the California Institute for Regenerative Medicine (grant INFR4-13597).

    ###

    [ad_2]

    University of California San Diego

    Source link

  • Chris Hemsworth receives ‘strong indication’ of a genetic predisposition to Alzheimer’s disease while filming new show | CNN

    Chris Hemsworth receives ‘strong indication’ of a genetic predisposition to Alzheimer’s disease while filming new show | CNN

    [ad_1]



    CNN
     — 

    Chris Hemsworth embarked on a personal and physically demanding journey for his new series “Limitless” that ultimately led to a sobering discovery.

    The “Thor” actor, 39, learns in one episode of the limited Disney+/National Geographic series – which shows him exploring ways to enhance his longevity and combat aging – that he has two copies of the APOE4 gene, one from each of his parents, meaning he has a heightened predisposition for developing Alzheimer’s disease.

    “They took all my bloodwork and did a bunch of tests and the plan was to on-camera tell me all the results and then talk about how you can improve this and that,” Hemsworth shared with Vanity Fair in an article published on Thursday. “And Peter Attia, who is the longevity doctor in that episode, and overseeing a lot of the show, called [“Limitless” creator] Darren [Aronofsky] and said, ‘I don’t want to tell him this on camera. We need to have an off-side conversation and see if he even wants this to be in the show.’ It was pretty shocking because he called me up and he told me.”

    Upon learning the news, Hemsworth said he “had a bunch of questions,” later adding that he “didn’t really know what to think. I was like, ‘Am I supposed to be worried? Is this concerning?’”

    He also said that the show then “became even more relevant and important for me, even more poignant than I ever thought it would be,” adding that APOE4 is “not a pre-deterministic gene, but it is a strong indication. Ten years ago, I think it was more thought of as determinant.”

    The new information, which Hemsworth said makes him “eight to 10 times more likely” to eventually develop Alzheimer’s disease, naturally caused him to reflect on death and his own mortality.

    “There was an intensity to navigating it. Most of us, we like to avoid speaking about death in the hope that we’ll somehow avoid it,” he told Vanity Fair. “We all have this belief that we’ll figure it out. Then to all of a sudden be told some big indicators are actually pointing to this as the route which is going to happen, the reality of it sinks in.”

    “Limitless,” which shows the Marvel star engaging in various stunts and practices to prolong and enhance his life, in fact deals with facing death in the final episode.

    “I think that’s my favorite episode. That’s where I worked with the death doula and people who worked in palliative care and end of life care and then spoke to a number of people who were at the end of their days or coming upon them – even younger people that were diagnosed with cancer and didn’t have long to live,” he shared.

    “Doing an episode on death and facing your own mortality made me go, ‘Oh God, I’m not ready to go yet,’” he later added. “I want to sit and be in this space with a greater sense of stillness and gratitude. And then you start talking about kids and family and going, ‘Oh my God, they’re getting older, they’re growing up and I keep slapping another movie on top of another movie.’ Before you know it, they’re 18 and they’ve moved out of house, and I missed the window.”

    In preparing the show for air, Hemsworth also mentioned that he was “offered a version of the episode where we didn’t talk about [his discovered genetic predisposition to Alzheimer’s],” but that the prospect of helping others helped him to get over any hesitation.

    “I thought, ‘No, look, if this is a motivator for people to take better care of themselves and also understand that there are steps you can take – then fantastic.’ My concern was I just didn’t want to manipulate it and overdramatize it, and make it into some sort of hokey grab at empathy or whatever for entertainment.”

    Hemsworth, who most recently appeared as the MCU’s God of Thunder in his fourth solo outing in this summer’s “Thor: Love and Thunder,” is next set to appear in another sequel, next year’s “Extraction 2.” He is also wrapping up a yet-to-be-revealed role in 2024’s “Furiosa,” costarring Anya Taylor-Joy, set in the universe of “Mad Max.”

    [ad_2]

    Source link

  • Newly Developed Gene Classifier Identifies Risk of Pre-Breast Cancer Progression

    Newly Developed Gene Classifier Identifies Risk of Pre-Breast Cancer Progression

    [ad_1]

    Newswise — DURHAM, N.C. – A team of researchers mapping a molecular atlas for ductal carcinoma in situ (DCIS) has made a major advance toward distinguishing whether the early pre-cancers in the breast will develop into invasive cancers or remain stable.

    Analyzing samples from patients who had undergone surgery to remove areas of DCIS, the team identified 812 genes associated with cancer progression. Using this gene classifier, they were then able to predict the risk of cancer cells recurring or progressing.

    The study, which published this week in the journal Cancer Cell, was led by E. Shelley Hwang, M.D., of the Duke Cancer Institute, and Rob West, M.D., Ph.D., of the Stanford University Medical Center. Their work is part of the Human Tumor Atlas Network under the Moonshot Initiative funded by the National Cancer Institute.

    “There has been a long-standing debate over whether DCIS is cancer or a high-risk condition,” Hwang said. “In the absence of a way to make that determination, we currently treat everyone with surgery, radiation, or both.

    “DCIS is diagnosed in more than 50,000 women a year, and about a third of those women have a mastectomy, so we are increasingly concerned that we might be overtreating many women,” Hwang said. “We need to understand the biology of DCIS better, and that’s what our research has been designed to do.”

    Hwang, West and colleagues analyzed 774 DCIS samples from 542 patients who were a median of 7.4 years post-treatment. They identified 812 genes associated with recurrence within five years from treatment.

    The gene classifier was able to predict both recurrence and invasive progression of cancer, with progression appearing to be dependent on a process that requires interactions between invasive DCIS cells and the unique features of the tumor environment.

    Hwang said most of the DCIS cancers analyzed in the study were identified to be at low risk for cancer progression or recurrence – a factor that underscores the need to have an accurate predictive model that can be used during clinical visits to guide care.

    “We’ve made great progress in our understanding of DCIS, and this work gives us a real path forward to being able to personalize care by scaling treatments to the risk of cancer progression,” Hwang said. “The real goal is diminishing treatment-related harms without compromising outcomes, and we are excited to be getting closer to achieving this for our patients with DCIS.”

    In addition to Hwang and West, study authors include co-principal investigator Carlo Maley, Ph.D., of Arizona State School of Life Sciences, and Graham Colditz, Ph.D., of Washington University at St. Louis, for the Breast Pre-Cancer Atlas Center, as well as collaborators from 12 other institutions as part of the Translational Breast Cancer Consortium.

    The study is part of the Human Tumor Atlas Network Consortium of the National Cancer Institute, which is part of the National Institutes of Health (R01 CA185138-01, U2C CA-17-035, UO1 CA214183, R01CA193694). Other funding support was from the Department of Defense (BC132057); The Breast Cancer Research Foundation (19-074, 19-028, 18-006); PRECISION CRUK Grand Challenge (AEI RYC2019- 026576-I); “la Caixa” Foundation (LCF/PR/PR17/51120011); the Lundbeck Foundation (R288-2018-35); the Danish Cancer Society (R229-A13616); and Susan G. Komen.

     

    ###

    [ad_2]

    Duke Health

    Source link

  • Gene plays important role in embryonic development

    Gene plays important role in embryonic development

    [ad_1]

    Newswise — An international study led by the medical Faculty of the University of Bonn has identified a gene that plays an important role in the development of the human embryo. If it is altered, malformations of various organ systems can result. The gene emerged very early in evolution. It also exists in zebrafish, for example, and performs a similar function there. The results have now been published in the Journal of Medical Genetics.

    The researchers tracked down the gene when they studied two individuals with congenital malformations. “It was a man and his niece,” explains Dr. Gabriel Dworschak. “Both had malformed kidneys, urinary tract and esophagus, and the man also had a malformed right arm and heart.”

    The physician at the University Children’s Hospital in Bonn conducts research on rare genetic diseases at the Institutes of Anatomy and Human Genetics. When the team looked at the genetic makeup of the family members, they came across an anomaly: A gene called SHROOM4 was altered in affected individuals compared to healthy individuals.

    SHROOM4 was already familiar from another context: It was known to play a key role in brain function. Mutations can result in intellectual impairment, epileptic seizures and behavioral abnormalities. “Our findings indicated though, that it may play a broader role in embryonic organ development,” Dworschak explains.

    The team from Bonn searched internationally for other cases in which abnormalities in the SHROOM4 gene had also been found – and succeeded: “Together with our cooperation partners, this led us to four more affected individuals from three families,” says Prof. Dr. Heiko Reutter, who has since moved from the University Hospital Bonn to the University of Erlangen-Nuremberg. “All of them had the SHROOM4 gene altered, but not always in the same way.”

    Zebrafish also needs SHROOM4

    However, this did not necessarily clarify whether SHROOM4 variants were actually responsible for the malformations. But there is an animal that has a very similar gene: the zebrafish. It serves as a model organism in many genetic studies today – and not only because it is easy to keep in a species-appropriate manner and to reproduce quickly: The skin of its larvae is almost transparent. This makes it easy to observe the animals’ embryonic development under the light microscope. “Here at the University Hospital, we have the advantage that the research group led by Prof. Dr. Benjamin Odermatt from the Institute of Neuroanatomy works a lot with zebrafish,” stresses Dr. Caroline Kolvenbach, who was also involved in the study of SHROOM4. “This expertise came in handy in our study.”

    The researchers almost completely inactivated SHROOM4 in the larvae. The animals then showed malformations similar to those seen in the patients. If, on the other hand, larvae with SHROOM4 switched off were injected with the intact human genetic material, they developed almost normally. “This shows first that they absolutely need a functional SHROOM4 for healthy development; and second, that the human gene can still take over the function of the fish gene,” Dworschak emphasizes.

    The team now wants to find out which part the gene plays in embryonic development. “We assume that it is needed for very basic processes in the cell,” says Dworschak. “It’s hard to explain otherwise why changes in the same gene cause such a variety of symptoms.”

    Small piece in the mosaic of an extremely complex picture

    How a mouse, a dog or a human being develops from a fertilized ovum is still not fully understood. This is because the ovum has the ability to form any type of tissue in the organism, whether it is bone, skin, muscle or the brain. Its daughter cells are genetically identical to it; so in principle they should be able to do the same. But at a very early stage, certain programs are activated in their cells that irrevocably determine their developmental fate.

    This process must be coordinated down to the finest detail. Because only then it is ensured that the eyes form in the appropriate spot on the face, while other cells very close by differentiate into the nasal cartilage. Surprisingly, however, there is no conductor wielding the baton. It is as if a Lego spaceship were assembling itself – only infinitely more complicated. “Our study is a small piece of the mosaic to this picture, which is still largely incomplete,” Dworschak says.

    Participating institutions and funding:

    In addition to the University of Bonn and the University Hospital Bonn, the study involved Children’s Mercy Hospital (USA), the Medical University of Silesia (Poland), the University of Zielona Góra (Poland), the University of Southern Denmark (Denmark), the University of Cologne, the University of Heidelberg, the University of Erlangen-Nuremberg, Medeor Hospital Lodz (Poland), and Goethe University Frankfurt. The work was supported by the German Research Foundation (DFG), the BONFOR program of the University Hospital Bonn, the Else Kröner-Fresenius Foundation, the Luise and Horst Köhler Foundation, and the National Institutes of Health (USA).

    Publication: Caroline M. Kolvenbach et al.: X-linked variations in SHROOM4 are implicated in congenital anomalies of the urinary tract, the anorectal, the cardiovascular, and the central nervous system; Journal of Medical Genetics; DOI: 10.1136/jmg-2022-108738

    [ad_2]

    University of Bonn

    Source link

  • 10,000 brains in a basement: The dark and mysterious origins of Denmark’s psychiatric brain collection | CNN

    10,000 brains in a basement: The dark and mysterious origins of Denmark’s psychiatric brain collection | CNN

    [ad_1]

    Editor’s Note: Watch the special documentary, “World’s Untold Stories: The Brain Collectors,” November 12-13 on CNN International.



    CNN
     — 

    For years, there had been whispers. Rumors swirled; stories exchanged. It wasn’t a secret, but it also wasn’t openly discussed, adding to a legend almost too incredible to believe.

    Yet those who knew the truth wanted it out.

    Tell everyone our story, they said, about the brains in the basement.

    As a child, Lise Søgaard remembers whispers, too, though these were different – the family secret kind, hushed because it was too painful to speak it out loud.

    Søgaard knew little about it, except that these whispers centered on a family member who seemed to exist solely in one photograph on the wall of her grandparent’s house in Denmark.

    The little girl in the picture was named Kirsten. She was the younger sister of Søgaard’s grandmother, Inger – that much she knew.

    “I remember looking at this girl and thinking, ‘Who is she?’ ‘What happened?’” Søgaard said. “But also this feeling of a little bit of a horror story there.”

    As she grew into adulthood, Søgaard continued to wonder. One day in 2020, she went to visit her grandmother, now in her mid-90s and living at a care home in Haderslev, Denmark. After all that time, she finally asked about Kirsten. Almost as if Inger had been waiting for that very question, the floodgates opened, and out poured a story Søgaard never expected.

    Kirsten Abildtrup was born on May 24, 1927, the youngest of five brothers and her sister, Inger. As a child, Inger remembers Kirsten as quiet and smart, the two sisters sharing a close bond. Then, when Kirsten was around 14 years old, something began to change.

    Kirsten experienced outbursts and prolonged bouts of crying. Inger asked her mother if it was her fault, often feeling that way because the two girls were so close.

    “At Christmas, they were supposed to go on a visit to some family members,” Søgaard said, “but my great-grandmother and father, they stayed home and sent all of their children away except for Kirsten.”

    When they got back from that family visit, Søgaard said, Kirsten was gone.

    It was the first of many hospitalizations, and the start of a long and painful journey that would ultimately end in Kirsten’s death.

    The diagnosis: schizophrenia.

    Kirsten was first hospitalized towards the end of World War II, when Denmark and the rest of Europe were at last on the verge of peace.

    Like so many places, Denmark was also grappling with mental illness. Psychiatric institutions had been built across the country to provide care for patients.

    Doctors prepare a patient for electroshock therapy at Augustenborg Psychiatric Hospital in Denmark, 1943.

    But there was limited understanding of what was happening in the brain. The same year peace came to Denmark’s doorstep, two doctors working in the country had an idea.

    When these patients died in psychiatric hospitals, autopsies were routinely performed. What if, these doctors thought, the brains were removed – and kept?

    Thomas Erslev, historian of medical science and research consultant at Aarhus University, estimates that half of all psychiatric patients in Denmark who died between 1945 and 1982 contributed – unknowingly and without consent – their brains. They went to what became known as the Institute of Brain Pathology, connected to the Risskov Psychiatric Hospital in Aarhus, Denmark.

    Doctors Erik Stromgren and Larus Einarson were the architects. After roughly five years, said Erslev, pathologist Knud Aage Lorentzen took over the institute, and spent the next three decades building the collection.

    Dr. Larus Einarson, shown here teaching a class, was one of the co-founders of the brain collection at the Institute of Brain Pathology.

    The final tally would amount to 9,479 human brains – believed to be the largest collection of its kind anywhere in the world.

    In 2018, pathologist Dr. Martin Wirenfeldt Nielsen got a call. The brain collection, as it would come to be known, was on the move.

    A lack of funding meant it could no longer stay in Aarhus, but the University of Southern Denmark in the city of Odense had offered to pick up the mantle. Would Wirenfeldt Nielsen be interested in overseeing it?

    Pathologist Dr. Martin Wirenfeldt Nielsen now oversees the brain collection, housed in Odense, Denmark.

    “I’d sort of heard of it in the periphery,” Wirenfeldt Nielsen recalled. “But my first real knowledge about the vast extent of it was when they decided to move it down here … (because) how do you actually move almost 10,000 brains?”

    The yellowish-green plastic buckets housing each brain, preserved in formaldehyde, were placed into new white buckets that were sturdier for the transport, and hand-labeled in black marker with a number. And then the brains, give or take a few (no one knows where bucket #1 is, for example) made their way to their new home in a large basement room on the university’s campus.

    “The room wasn’t actually ready when they moved it down here,” Wirenfeldt Nielsen said. “The whole collection was just standing there, buckets on top of each other, in the middle of the floor. And that’s when I saw it for the first time … That was like, okay, this is something I’ve never seen before.”

    Eventually, the nearly 10,000 buckets were placed on rolling shelves, where they remain today – waiting – representing lives, and a range of psychiatric disorders.

    There are roughly 5,500 brains with dementia; 1,400 with schizophrenia; 400 with bi-polar disorder; 300 with depression, and more.

    What separates this collection from any other in the world is that the brains collected during the first decade are untouched by modern medicines – a time capsule of sorts, for mental illness in the brain.

    “Whereas other brain collections … (are) maybe specified for neurodegenerative diseases, dementia, tumors, or other things like that – we really have the whole thing here,” Wirenfeldt Nielsen said.

    But it has not been without controversy. In the 1990s, the Danish public got wind of the collection, which had been sitting idle since former director Lorentzen’s retirement in 1982.

    It would kick off one of the first major ethical science debates in Denmark.

    A history of The Brain Collection

    1945

    The Institute of Brain Pathology is founded, connected to the Risskov Psychiatric Hospital in Aarhus, Denmark

    Risskov, pictured here in the early 1900s.

    Credit: Museum Ovartaci

    1945-1982

    Nearly 9,500 brains are collected without permission from deceased psychiatric patients across the country

    Brains were collected and sent from Danish hospitals, including Rigshospitalet (pictured) in Copenhagen.

    Credit: Jesper Vaczy/Medical Museum

    1982

    The head of the brain collection, Knud Aage Lorentzen, retires. Nobody takes his place, and the collection sits untouched in a basement

    The brains, shown here in their original yellow buckets, would remain largely untouched for more than 20 years.

    Credit: Hanne Engelstoft

    1987

    The Danish Council of Ethics is established

    The Council of Ethics is an independent group formed to advise the Danish parliament (pictured here in 2016) on ethical matters.

    Credit: olli0815/iStock/Getty Images

    1991

    After the Council of Ethics says the brains can be used with certain restrictions in place, SIND (Denmark’s national association for psychiatric health) demands the brains be buried – sparking one of the first major ethical science debates in Denmark

    Some pieces of brain material are preserved in paraffin wax.

    Credit: Hanne Engelstoft

    2005

    Danish scientist Karl-Anton Dorph-Petersen takes over the collection’s daily maintenance at Aarhus

    Karl-Anton Dorph-Petersen helped revive and preserve the collection in the mid-2000s.

    Credit: Hanne Engelstoft

    2006

    The Council of Ethics goes against political and religious demands by ruling it is ethically sound to use deceased psychiatric patient brains for research without getting the consent of relatives. This time, SIND agrees

    The collection includes patient records and tissue preserved on slides, such as these.

    Credit: Hanne Engelstoft

    2017-2018

    A lack of funding threatens the brains, and the collection is saved by moving it to Odense, where Dr. Martin Wirenfeldt Nielsen takes over

    The brains were put into new white buckets to move to Odense, where they remain safely stored on rolling shelves.

    Credit: Samantha Bresnahan/CNN

    Source: Thomas Erslev, historian of medical science

    Graphic: Woojin Lee, CNN

    “There was a discussion back and forth, and one position was that we should destroy the collection – either bury the brains or get rid of them in any other ethical way,” said Knud Kristensen, the director of SIND, the Danish national association for mental health, from 2009 to 2021, and current member of Denmark’s Ethical Council. “The other position said, okay, we already did harm once. Then the least we can do to those patients and their relatives is to make sure that the brains are used in research.”

    After years of intense debate, SIND changed its position. “All of a sudden, they were very strong proponents for keeping the brains,” Erslev said, “actually saying this might be a very valuable resource, not only for the scientists, but for the sufferers of psychiatric illness because it might prove to benefit therapeutics down the line.”

    “For (SIND),” Kristensen said, “It was important where it was placed and to make sure that there would be some sort of control of the future use of the collection.”

    By the time it moved to Odense in 2018, the ethical debate was largely settled, and Wirenfeldt Nielsen became caretaker of the collection.

    A few years later, he would get a message from Søgaard. Was it possible, she asked, that he had a brain there belonging to a woman named Kirsten?

    In the search for what happened to her great aunt Kirsten, Søgaard realized there were clues all around her. But piecing together what exactly had happened to her grandmother’s sister was slow, filled with dead ends and false starts.

    Yet she was enthralled, and began officially reporting her journey for Kristeligt Dagblad, the Copenhagen-based newspaper where she worked – eventually bringing it to light in a series of articles.

    At one point, Søgaard decided to focus on a single word her grandmother had told her, the name of a psychiatric hospital: Oringe.

    “I opened my computer and I searched for ‘Oringe patient journals,’” she said. After putting in a request through the national archives, “I got an email that said, ‘Okay, we found something for you, come have a look if you want.’ … I felt this excitement … like, she’s out there.”

    Journalist Lise Søgaard made it her mission to find out what happened to her grandmother's little sister, Kirsten -- a journey that would take her places she never imagined. She shared that experience with CNN's Dr. Sanjay Gupta at her home outside Copenhagen in April 2022.

    That excitement was short-lived. At the national archives, they placed a mostly empty file in front of her. It wasn’t much to go on, but it confirmed Kirsten’s diagnosis of schizophrenia.

    Without another solid lead, Søgaard wondered where to go next. Then, almost in passing, as they looked through old family photos together, her mother said something that she’d never heard before.

    “She said, ‘You know, they might have kept her brain,’ and I said, ‘What?!’” Søgaard told CNN’s Dr. Sanjay Gupta at her house outside of Copenhagen. “And she told me what she knew about the brain collection.”

    At age 95, Søgaard’s grandmother, Inger, could still clearly picture visiting her little sister Kirsten in the hospital, after the symptoms she first started experiencing at age 14 continued to progress.

    Upon one visit, Inger remembered, “(Kirsten) was lying there, completely apathetic. She was not able to speak to us. … Another day we went to visit her, and she was gone from her room. They told us she had thrown a glass at a nurse, and they had sent her to the basement, to a room where they (restrained) her with belts. And we were not allowed to go in, but I saw her through a hole in the door; she was lying there, strapped up.”

    One floor of the Oringe psychiatric hospital is now a museum, which displays medical treatments and patient rooms such as this one.

    Inger felt confused and scared, she said, because it could have been anyone, including her, that might get “sick.”

    At Sankt Hans, one of the largest and oldest psychiatric hospitals in Denmark, Dr. Thomas Werge walks the same grounds he did as a child, when his own grandmother was hospitalized there. Now, he runs the Institute for Biological Psychiatry there, where he and his team study the biological causes that contribute to psychiatric disorders.

    A 2012 study found that roughly 40% of Danish women and 30% of Danish men had received treatment for a mental health disorder in their lifetimes – though Werge estimated that number would “almost certainly” be higher if the same study was done today. (By comparison, that same year, less than 15% of US adults received mental health services.) Among the other Nordic countries, including Sweden and Norway, Werge said the numbers would be comparable to Denmark’s, as there are “similar [universal] health care systems and standards for admission.”

    “Mental (health) disorders are all over,” he added. “We just do not recognize this when we walk around among people. Not everybody carries their pain on the outside.”

    For schizophrenia, there are no blood tests or biomarkers to signify its presence; instead, doctors must rely only on a clinical exam.

    Schizophrenia presents itself in what the World Health Organization (WHO) calls “significant impairments in the way reality is perceived,” causing psychosis that can include delusions, hallucinations, disorganized behavior or thoughts, and extreme agitation.

    Roughly one in 300 people are affected by schizophrenia worldwide, according to the WHO, but less than one-third of those will ever receive specialist mental health care.

    denmark cemetery of the brainless spc intl_00013202.png

    Visiting a ‘cemetery of the brainless’ in Denmark


    02:10

    – Source:
    CNN

    The standard treatment since the mid-1950s has been anti-psychotic drugs, which typically work by manipulating dopamine levels: the brain’s reward system. But, Werge said, it can come with a cost.

    “Schizophrenia and psychosis are linked to creativity,” he said. “So, when you try to inhibit the psychosis, you also inhibit the creativity. So, there’s a price for being medicated … Whatever causes all these problems for humans is also what makes us humans in the good sense.”

    Though there haven’t been many significant scientific breakthroughs regarding an understanding of the disease, researchers have confirmed that genetics and heritability play a significant role.

    According to Werge, the heritability estimate is as high as 80% – the same as height. “It’s not a surprise to people that if you have very tall parents … there’s a lot of genetics in that,” he said. “The genetic component is equally large in most of the mental disorders actually.”

    Those inherited genetic factors either come from the parents, he added, or can arise in a child even if the parents don’t carry the gene.

    Søgaard, who has two young children, said the genetic connection was not a driving motivator in her mission to find out what happened to Kirsten, but she has thought about what it means for herself and her family.

    When families reach out about possible relatives in the brain collection, “that’s an ethical dilemma that we need to take into consideration,” Wirenfeldt Nielsen said. In Søgaard’s case, she received approval for the Danish National Archives to check the set of black books that contain the names of every person whose brain is in the collection.

    There on the list was Kirsten’s name.

    “I got an email back [from the National Archives], and they scanned the page where Kirsten’s name was, and her birthday, and the day they received the brain. And in the column out to the left, there was a number,” Søgaard remembered. “Number 738.” She immediately wrote an email to Wirenfeldt Nielsen, asking if that number corresponded to the bucket with Kirsten’s brain.

    “I said, ‘Yes, that’s it,’” Wirenfeldt Nielsen recalled. But he also said he couldn’t be sure the bucket was there because a few are missing for unknown reasons. He ventured down to the basement storage room to verify it was there.

    On one of the rolling shelves sat bucket #738.

    Kirsten’s brain.

    Bucket #738 -- Kirsten's brain -- sits on a shelf among the rest of the brain collection in the basement at the University of Southern Denmark in Odense.

    When Søgaard first saw it, she felt compelled to hug the bucket.

    “I had learned a lot about Kirsten,” she said. “I feel some kind of connection … (and) I know the pain that she felt, and I know what she went through.”

    What Kirsten went through was another extraordinary beat in this incredible story, and the long history of psychiatric care in Denmark.

    As part of her treatment, Kirsten received what’s known commonly in Denmark as “the white cut.”

    In medical terms: a lobotomy.

    The procedure was an integral part of the country’s psychiatric history. During the time the brain collection was running from the 1940s until the early 1980s, Denmark reportedly did more lobotomies per capita than any other country in the world.

    01 denmark brain sanjay

    A look at the brain like you’ve never seen it before


    03:08

    – Source:
    CNN

    “It’s a very poor treatment, because you destroy a big part of the brain,” Wirenfeldt Nielsen said. “And it’s very risky, because you can kill the patient, basically – but they had nothing else to do.”

    Treatment options were limited, and in many ways extreme. Seizures were induced by placing electrodes on either side of the head; insulin shock therapy meant patients were administered large doses of insulin, reducing blood sugar and resulting in a comatose state; and the lobotomy, either transorbital – using a pick-like instrument inserted through the back of the eye to the front lobe – or prefrontal.

    The prefrontal lobotomy was pioneered by a Portuguese neurologist, Antonio Egas Moniz. Now considered barbaric, he actually won the Nobel Prize for the procedure in 1949.

    A tool is inserted into the frontal lobe, scraping away tracts of white matter – the reason behind the “white cut” moniker. “Emotional reactions … are located at least in part in the frontal lobe,” explained Wirenfeldt Nielsen, “so they thought that just by cutting (there), that could sort of calm the patient down.”

    Left: Portuguese neurologist Antonio Egas Moniz was awarded the Nobel Prize in 1949 for pioneering the prefrontal lobotomy.
Upper right: Lobotomies became a popular treatment option from the 1930s to the early 1950s. Here, a surgeon drills into a patient's skull at a hospital in England, 1946.
Lower right: By cutting tracts through brain matter in the frontal lobe, the belief was the lobotomy could treat symptoms of mental illness.

    In Kirsten’s case, Inger said there were glimpses of “the old Kirsten” before she got the white cut – but after that, she was gone. In 1951, the year after her lobotomy, Kirsten died.

    She was just 24 years old.

    On a metal table in a small, standalone building on the grounds of Oringe psychiatric hospital, Kirsten’s brain was removed, set into a small plastic bucket, placed in a wooden box, and shipped – by regular mail carrier – to the Institute of Brain Pathology at Risskov, to join the brain collection.

    Søgaard saw the metal table, where a white wooden block still sits on one end – where the heads were placed – and upon which small marks are still visible today. This is where the skulls were opened.

    The standalone building at Oringe (left) housing the autopsy room where Kirsten's brain was removed in 1951 still stands today, and includes the wooden boxes (right) that were once used to ship the brains to Risskov.

    Despite the graphic reminders, in reporting out this story both for herself, and for the newspaper, “it was important (for me) to not write a story that was a horror story,” she said, adding it was easy to look back and say, “How could you do that?”

    “I don’t think the doctors wanted to do bad. I think they actually wanted to do good. … I think the most ethical thing you can do is to make sure that you know exactly what you can do with these brains. And that’s what they’re doing now. They’re trying to find out, ‘How can they help us?’”

    There have been studies using the collection over the years, including a discovery in 1970 of what is now known as familial Danish dementia, and a new study is ongoing, focused on mRNA in the brains, by Danish researcher Betina Elfving.

    For the most part, the brains represent untapped, enormous potential. Yet the one in bucket #738 has already done something extraordinary, thanks in large part to Søgaard herself. She worked to break the cycle of stigma surrounding mental health disorders by sharing her most personal, intimate family details with the world.

    “(My grandmother) expressed gratitude,” Søgaard said. “She also said, ‘I feel like I’m moving closer to my sister now.’”

    [ad_2]

    Source link